Literature DB >> 26774690

Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS.

Stephanie M Gallitano1, Laura McDermott2, Kanwaljit Brar3, Eve Lowenstein2.   

Abstract

Patients with HIV and AIDS are living longer because of advancements in antiretroviral therapy. These patients are often susceptible to debilitating inflammatory disorders that are refractory to standard treatment. We discuss the relationship of tumor necrosis factor-alpha and HIV and then review 27 published cases of patients with HIV being treated with tumor necrosis factor-alpha inhibitors. This review is limited because no randomized controlled trials have been performed with this patient population. Regardless, we propose that reliable seropositive patients, who are adherent to medication regimens and frequent monitoring and have failed other treatment modalities, should be considered for treatment with tumor necrosis factor-alpha inhibitors.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AIDS; HIV; autoimmune disease; hidradenitis suppurativa; inflammatory bowel disease; opportunistic infections; psoriasis; rheumatoid arthritis; tumor necrosis factor-alpha

Mesh:

Substances:

Year:  2016        PMID: 26774690     DOI: 10.1016/j.jaad.2015.11.043

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  18 in total

Review 1.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

Review 2.  Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience.

Authors:  Paul Sator
Journal:  Ther Adv Chronic Dis       Date:  2018-05-22       Impact factor: 5.091

3.  Successful treatment of severe perianal Crohn's disease with infliximab in an HIV-positive patient.

Authors:  Maria Ana Rafael; Luís Carvalho Lourenço; Ana Maria Oliveira; Teresa Branco; Carla Carneiro; Ana Costa; Jorge Reis
Journal:  Clin J Gastroenterol       Date:  2019-05-20

Review 4.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

5.  Erythrodermic psoriasis and human immunodeficiency virus: association and therapeutic challenges.

Authors:  Fernando Valenzuela; Javier Fernández; Margarita Sánchez; Andrea Zamudio
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

6.  Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review.

Authors:  Bridget Myers; Quinn Thibodeaux; Vidhatha Reddy; Stephanie Chan; Nicholas Brownstone; Wilson Liao; Tina Bhutani
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2020-09-16

7.  Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases.

Authors:  Sintawat Wangsiricharoen; Colin Ligon; Lydia Gedmintas; Admad Dehrab; Marisa Tungsiripat; Clifton Bingham; Carlos Lozada; Leonard Calabrese
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03       Impact factor: 4.794

Review 8.  Assessment and management of musculoskeletal disorders among patients living with HIV.

Authors:  Karen Walker-Bone; Erin Doherty; Kaushik Sanyal; Duncan Churchill
Journal:  Rheumatology (Oxford)       Date:  2017-10-01       Impact factor: 7.580

9.  HIV Nef- and Notch1-dependent Endocytosis of ADAM17 Induces Vesicular TNF Secretion in Chronic HIV Infection.

Authors:  Christian Ostalecki; Sebastian Wittki; Jung-Hyun Lee; Miriam M Geist; Nadine Tibroni; Thomas Harrer; Gerold Schuler; Oliver T Fackler; Andreas S Baur
Journal:  EBioMedicine       Date:  2016-10-19       Impact factor: 8.143

Review 10.  Natural killer cells in antiviral immunity.

Authors:  Niklas K Björkström; Benedikt Strunz; Hans-Gustaf Ljunggren
Journal:  Nat Rev Immunol       Date:  2021-06-11       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.